Twist Bioscience Co. (NASDAQ:TWST) Receives $54.40 Average Price Target from Brokerages

Shares of Twist Bioscience Co. (NASDAQ:TWST) have received a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $54.40.

Several research analysts have commented on TWST shares. Robert W. Baird boosted their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. TD Cowen restated a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. Wolfe Research initiated coverage on shares of Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Finally, JPMorgan Chase & Co. upped their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a report on Tuesday, February 4th.

Insider Activity

In related news, SVP Paula Green sold 860 shares of the stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $52.70, for a total value of $45,322.00. Following the sale, the senior vice president now directly owns 133,715 shares of the company’s stock, valued at approximately $7,046,780.50. This represents a 0.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert Chess sold 3,504 shares of the stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $51.85, for a total transaction of $181,682.40. Following the completion of the sale, the director now directly owns 21,641 shares in the company, valued at approximately $1,122,085.85. The trade was a 13.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 37,180 shares of company stock worth $1,821,971 in the last 90 days. 3.01% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Twist Bioscience

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in shares of Twist Bioscience by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company’s stock worth $269,860,000 after purchasing an additional 189,791 shares during the last quarter. ARK Investment Management LLC boosted its stake in shares of Twist Bioscience by 4.4% during the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock worth $260,040,000 after purchasing an additional 237,772 shares during the last quarter. State Street Corp boosted its stake in shares of Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of Twist Bioscience by 54.6% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company’s stock worth $69,972,000 after purchasing an additional 532,040 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Twist Bioscience by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company’s stock worth $63,895,000 after purchasing an additional 6,908 shares during the last quarter.

Twist Bioscience Trading Up 0.7 %

NASDAQ TWST opened at $38.82 on Thursday. Twist Bioscience has a one year low of $27.41 and a one year high of $60.90. The firm has a 50 day simple moving average of $47.45 and a 200-day simple moving average of $45.60. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. The firm has a market cap of $2.32 billion, a price-to-earnings ratio of -11.49 and a beta of 1.87.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. During the same quarter in the previous year, the business posted ($0.75) EPS. The firm’s revenue was up 24.1% on a year-over-year basis. Equities research analysts anticipate that Twist Bioscience will post -2.12 EPS for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.